评价硬性透气角膜接触镜配戴者使用硬性透气角膜接触镜润滑液有效性及安全性的前瞻性、多中心、随机、平行阳性对照临床研究

注册号:

Registration number:

ChiCTR2300069668 

最近更新日期:

Date of Last Refreshed on:

2023-08-13 16:37:16 

注册时间:

Date of Registration:

2023-03-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

评价硬性透气角膜接触镜配戴者使用硬性透气角膜接触镜润滑液有效性及安全性的前瞻性、多中心、随机、平行阳性对照临床研究

Public title:

Prospective, multicenter, randomized, parallel positive controlled clinical study to evaluate the efficacy and safety of rigid gas permeable contact lens lubrication for wearers of rigid breathable contact lenses

注册题目简写:

English Acronym:

研究课题的正式科学名称:

评价硬性透气角膜接触镜配戴者使用硬性透气角膜接触镜润滑液有效性及安全性的前瞻性、多中心、随机、平行阳性对照临床研究

Scientific title:

Prospective, multicenter, randomized, parallel positive controlled clinical study to evaluate the efficacy and safety of rigid gas permeable contact lens lubrication for wearers of rigid breathable contact lenses

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

何沁瑶 

研究负责人:

刘陇黔 

Applicant:

Qinyao He 

Study leader:

Longqian Liu 

申请注册联系人电话:

Applicant telephone:

+86 13952639590

研究负责人电话:

Study leader's
telephone:

+86 13708000190

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

qinyao.he@visionxmed.com

研究负责人电子邮件:

Study leader's E-mail:

bq15651@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市闵行区新骏环路245号D栋103室

研究负责人通讯地址:

四川省成都市武侯区国学巷37号

Applicant address:

Room 103, Building D, 245 Xinjunhuan Road, Minhang District, Shanghai

Study leader's address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海艾康特医疗科技有限公司

Applicant's institution:

Shanghai Icon Medical Technology Co., Ltd

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

West China Hospital of Sichuan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022年临床试验(器械)审(87)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院临床试验伦理审查委员会

Name of the ethic committee:

Clinical Trial Ethics Review Committee, West China Hospital, Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-01-04 00:00:00

伦理委员会联系人:

李娜

Contact Name of the ethic committee:

Na Li

伦理委员会联系地址:

四川省成都市武侯区国学巷37号

Contact Address of the ethic committee:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 85423237

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital of Sichuan University

研究实施负责(组长)单位地址:

四川省成都市武侯区国学巷37号

Primary sponsor's address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

珠海

Country:

China

Province:

Guangdong

City:

Zhuhai

单位(医院):

珠海溪谷医疗科技有限公司

具体地址:

广东省珠海市金湾区三灶镇机场西路628号珠海国际健康港的GMP生产车间10栋1、4层

Institution
hospital:

Zhuhai Xigu Medical Technology Co., Ltd

Address:

Floor 1 and 4, Building 10, GMP Production Workshop, Zhuhai International Health Port, 628 Airport West Road, Sanzao Town, Jinwan District, Zhuhai, Guangdong

经费或物资来源:

申办方

Source(s) of funding:

Sponsor

研究疾病:

硬性透气角膜接触镜配戴者  

Target disease:

Rigid gas permeable contact lens wearers

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评估硬性透气角膜接触镜配戴者使用珠海溪谷医疗科技有限公司生产的硬性透气角膜接触镜润滑液的有效性及安全性。  

Objectives of Study:

To evaluate the effectiveness and safety of rigid gas permeable contact lens wearers using rigid breathable contact lens lubricant produced by Zhuhai Xigu Medical Technology Co., LTD.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 单眼符合入选标准; 2. 患有可能影响眼部的全身性疾病,如糖尿病,唐氏综合症,甲亢、类风湿性关节炎,2年内有鼻窦炎病史或其他研究者认为不能配戴硬性透气性角膜接触镜的疾病; 3. 患有某些影响硬性接触镜配戴的眼部疾患:如眼部急性或慢性眼病,春季卡他性结膜炎、青光眼、干眼症(BUT<5s)、角膜异常等; 4. 有接触镜或接触镜护理液过敏史的患者; 5. 正在使用或研究期间需要使用可能会导致干眼或影响视力及角膜曲率等药物(免疫抑制剂、糖皮质激素、降眼压药物、低浓度阿托品)的患者; 6. 有过内眼手术史者; 7. 眼压异常(正常的眼压范围为10~21mmHg,双眼眼压差异应≤5mmHg)患者; 8. 筛选前90天内参加其他药物临床试验,30天内参加其他医疗器械临床试验者; 9. 既往30天内配戴过硬性接触镜(包括角膜塑形镜)的患者; 10. 入组时为孕妇、哺乳期或近期计划怀孕者; 11. 不能按医嘱随访者; 12. 检查结果提示有配戴禁忌症或不适合配戴硬性接触镜的患者; 13. 研究者判断患者不适合入选的其它情况。

Exclusion criteria:

1. A single eye meets the inclusion criteria; 2. Have a systemic medical condition that may affect the eyes, such as diabetes mellitus, Down syndrome, hyperthyroidism, rheumatoid arthritis, a history of sinusitis within 2 years, or other medical conditions that are considered unacceptable for wearing a rigid breathable contact lens; 3. Patients with certain eye diseases affecting the wearing of rigid contact lenses, such as acute or chronic eye diseases, catarral conjunctivitis in spring, glaucoma, dry eye (BUT < 5s), corneal abnormalities, etc. 4. Patients with allergic history of contact lens or contact lens solution; 5. Patients who are using or need to use drugs that may cause dry eyes or affect vision and corneal curvature (immunosuppressants, glucocorticoids, intraocular pressure lowering drugs, low concentration atropine) during the study; 6. Patients with a history of internal eye surgery; 7. Patients with abnormal intraocular pressure (normal intraocular pressure ranges from 10 to 21mmHg, and the difference between binocular pressure should be less than or equal to 5mmHg); 8. Participants in clinical trials of other drugs within 90 days and clinical trials of other medical devices within 30 days before screening; 9. Patients who have worn rigid contact lenses (including orthokeratology lenses) within the previous 30 days; 10. Pregnant, lactating or planning to become pregnant at the time of enrollment; 11. Cannot follow the doctor's advice; 12. Patients with contraindications for wearing rigid contact lenses or unsuitable for wearing rigid contact lenses as indicated by examination results; 13. Other conditions for which the investigator judged the patient unsuitable for inclusion.

研究实施时间:

Study execute time:

From 2023-01-04 00:00:00 To 2023-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-04-01 00:00:00 To 2023-08-31 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

78

Group:

Experimental group

Sample size:

干预措施:

硬性透气角膜接触镜润滑液

干预措施代码:

Intervention:

Rigid gas permeable contact lens lubricant

Intervention code:

组别:

对照组

样本量:

78

Group:

Control group

Sample size:

干预措施:

隐形眼镜润滑液

干预措施代码:

Intervention:

Contact lens lubricant

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院 

单位级别:

三甲 

Institution
hospital:

West China Hospital of Sichuan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

温州 

Country:

China

Province:

Zhejiang

City:

Wenzhou

单位(医院):

温州医科大学附属眼视光医院 

单位级别:

三甲 

Institution
hospital:

Optometry Hospital Affiliated to Wenzhou Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China

Province:

Shaanxi

City:

Xi'an

单位(医院):

西安市人民医院 

单位级别:

三甲 

Institution
hospital:

Xi'an People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

戴镜后30天的双眼舒适度均≥3级的比例

指标类型:

主要指标

Outcome:

The proportion of binocular comfort >= Level 3 30 days after wearing glasses

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

戴镜后30天的双眼戴镜最佳矫正视力均≥5.0的比例

指标类型:

主要指标

Outcome:

Proportion of optimal corrected visual acuity >= 5.0 for both eyes 30 days after wearing glasses

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

发镜、戴镜后1天、7天和90天的双眼舒适度

指标类型:

次要指标

Outcome:

Binocular comfort at 1, 7 and 90 days after hair and wear

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

发镜、戴镜后1天、7天和90天的双眼戴镜最佳矫正视力

指标类型:

次要指标

Outcome:

The best corrected visual acuity with glasses on both eyes at 1 day, 7 days and 90 days after wearing glasses

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

戴镜后1天、7天、30天和90天的双眼裸眼视力及残余屈光度

指标类型:

次要指标

Outcome:

Binocular naked eye visual acuity and residual diopter at 1, 7, 30, and 90 days after wearing glasses

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

发镜、戴镜后1天、7天、30天和90天的双眼戴镜视力

指标类型:

次要指标

Outcome:

Visual acuity in both eyes at 1, 7, 30, and 90 days after wearing glasses

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主观可接受度评价:评估受试者发镜、戴镜后1天、7天、30天和90天对于视觉、可操作性、镜片清洁性的接受程度。

指标类型:

次要指标

Outcome:

Subjective acceptability evaluation: The subject's acceptability for vision, operability, and lens cleanliness was evaluated at 1, 7, 30, and 90 days after the lens was put on and worn.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 8 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究者使用随机系统随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomized by the investigator using a random system

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

NA

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-03-23 02:48:43